旺山旺水新冠口服药有抑制尼帕病毒潜力，但距离应用还很远

Core Viewpoint - The recent emergence of Nipah virus cases in West Bengal, India, with a mortality rate exceeding 40%, has raised significant concerns, especially given the lack of specific vaccines and effective treatments. A promising oral nucleoside drug, VV116, has shown significant antiviral activity against the Nipah virus, offering new hope for treatment and prevention [3][5]. Group 1: Drug Development and Efficacy - VV116 (hydrobromide deuterated remdesivir) is a novel oral nucleoside antiviral drug that has been approved for COVID-19 treatment in Uzbekistan and China. It targets viral RNA-dependent RNA polymerase (RdRp) and has demonstrated significant inhibitory activity against both Malaysian (NiV-M) and Bangladeshi (NiV-B) strains of the Nipah virus in vitro [5]. - In a lethal dose infection model using golden hamsters, VV116 administered at a dose of 400 mg/kg increased the survival rate of the animals to 66.7% and significantly reduced viral loads in the lungs, spleen, and brain [5]. - The research from the Wuhan Institute of Virology confirms VV116's potential for treating Nipah virus infections, suggesting it could serve as a preventive medication for high-risk groups such as healthcare workers and laboratory personnel [5]. Group 2: Market Reaction and Future Prospects - Following the announcement of VV116's efficacy against the Nipah virus, the stock of its parent company, Wangshan Wangshui (02630.HK), surged over 10% in intraday trading on January 27 [6]. - Despite the promising results, VV116 is still in the preclinical research stage and must undergo human clinical trials, regulatory approval, and market entry before it can be effectively used against the Nipah virus [6]. - The Nipah virus has a history of outbreaks since 1998 in Malaysia, Singapore, India, and Bangladesh, but the lack of effective vaccines and treatments has been attributed to insufficient funding for research and the relatively low number of cases, despite its high mortality rate [6].